基于RSM和AI的机器学习,以通过设计开发Rivaroxaban推拉式透片的质量及其PBPK建模
Muhammad Talha Saleem1, Muhammad Harris Shoaib2, Rabia Ismail Yousuf1
1Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, 75270, Pakistan.
人工神经网络 (ANN) 和响应表面方法 (RSM) 优化控制释放的里瓦洛克萨班 (RVX) 透片. ANN有效地模拟复杂药物释放,与即时释放配方相比,提高了生物可用性.
科学领域:
- 制药技术 制药技术 制药技术
- 计算化学的计算化学
- 药理动力学 药理动力学
背景情况:
- 开发可控释放药物递送系统对于提高治疗疗效和患者服药性至关重要.
- 里瓦罗克萨班 (RVX) 是一种抗凝剂,需要精确的剂量来管理血栓事件.
- 透性平板技术为零顺序药物释放配置文件提供了一个有前途的平台.
研究的目的:
- 使用人工神经网络 (ANN) 和响应表面方法 (RSM) 开发和优化可控释放里瓦洛克萨班 (RVX) 透片.
- 研究配方变量对RVX释放动力学的影响.
- 使用生理学基础的药代动力学 (PBPK) 建模预测体内性能.
主要方法:
- 人工神经网络 (ANN) 和响应表面方法 (RSM) 的应用,以优化配方.
- 中央复合设计 (CCD) 用于生成用于ANN模型培训的实验数据.
- 在体外释放药物的研究,以评估RVX释放概况.
- 使用GastroPlusTM进行体内仿真的生理学基础药理动力学 (PBPK) 建模.
主要成果:
- 实现了高达12小时的RVX零顺序释放.
- ANN模型成功地预测了针对RSM优化的配方进行交叉验证的优化配方.
- 预测和优化配方 (ANOVA) 之间没有发现显著差异.
- 与立即释放片相比,PBPK建模表明,在禁食 (82%) 和食 (98.5%) 状态下,奥斯莫斯片的生物可用性提高.
结论:
- 由于其处理非线性关系的能力,ANN是优化复杂的透药物递送系统的有效工具.
- 开发的RVX透片显示出改善体内性能和生物可用性的潜力.
- 这种方法为设计先进的可控释放配方提供了一个强大的框架.
更多相关视频
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
06:00Optimization of the Epimedii Folium Mutton-Oil Processing Technology and Testing Its Effect on Zebrafish Embryonic Development
Published on: March 17, 2023
相关概念视频
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
Analysis of Population Pharmacokinetic Data
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution
